PMID- 31078062
OWN - NLM
STAT- MEDLINE
DCOM- 20191211
LR  - 20191217
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 172
DP  - 2019 Aug 5
TI  - An immunosensing device based on inhibition of mediator's faradaic process for 
      early diagnosis of prostate cancer using bifunctional nanoplatform reinforced by 
      carbon nanotube.
PG  - 259-267
LID - S0731-7085(19)30549-7 [pii]
LID - 10.1016/j.jpba.2019.05.008 [doi]
AB  - In this study, a simple and lable-free voltammetric immunosensor was successfully 
      developed for the ultrasensitive detection of prostate specific antigen (PSA). To 
      do this, multiwalled carbon nanotube (MWCNT)/L-histidine functionalized reduced 
      graphene oxide (His-rGO) was demonstrated as a bifunctional nanoplatform for 
      covalently attaching thionine redox indicator and anti-PSA antibody (Ab). The 
      MWCNT enhanced electrical conductivity and facilitated the electron transfer 
      between thionine and the glassy carbon electrode. While, the presence of anti-PSA 
      antibody blocked the electron transfer of thionine and decreased redox signals. 
      The principle response of proposed immunosensor was based on the selective 
      interaction of PSA with thionine-NH(2)-GO-COOH-Ab. This selective interaction led 
      to further decrease of response current of attached electrochemical probe. The 
      liner calibration curve for tumor marker determination was 10 fg mL(-1)-20 ng 
      mL(-1) (R(2) = 0.996). Under optimized conditions, the immunosensor was able to 
      selectively detect PSA with a limit of detection (LOD) of 2.8 fg mL(-1) at 3sigma. 
      The relative standard deviations (RSDs) for single-electrode repeatability and 
      electrode-to-electrode reproducibility were less than 2.9% and 5.7% (n = 5), 
      respectively. Furthermore, the as-proposed immunosensor showed excellent 
      performance in detection of PSA in the human serum and saliva samples, which 
      implies that the current strategy has a promising feature for the clinical 
      assessment of tumor marker status in patients with prostate cancer.
CI  - Published by Elsevier B.V.
FAU - Farzin, Leila
AU  - Farzin L
AD  - Radiation Application Research School, Nuclear Science and Technology Research 
      Institute, Tehran, Iran. Electronic address: lfarzin84@yahoo.com.
FAU - Sadjadi, Sodeh
AU  - Sadjadi S
AD  - Material and Nuclear fuel school, Nuclear Science and Technology Research 
      Institute, Tehran, Iran.
FAU - Shamsipur, Mojtaba
AU  - Shamsipur M
AD  - Department of Chemistry, Razi University, Kermanshah, Iran. Electronic address: 
      mshamsipur@yahoo.com.
FAU - Sheibani, Shahab
AU  - Sheibani S
AD  - Radiation Application Research School, Nuclear Science and Technology Research 
      Institute, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20190505
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Nanotubes, Carbon)
RN  - 0 (Oxides)
RN  - 7440-57-5 (Gold)
RN  - 7782-42-5 (Graphite)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Biomarkers, Tumor/metabolism
MH  - Biosensing Techniques/*instrumentation
MH  - Early Detection of Cancer/*instrumentation
MH  - Electrochemical Techniques/instrumentation
MH  - Electrodes
MH  - Gold/chemistry
MH  - Graphite/chemistry
MH  - Humans
MH  - Immunoassay/*instrumentation
MH  - Limit of Detection
MH  - Male
MH  - Metal Nanoparticles/chemistry
MH  - Nanotubes, Carbon/*chemistry
MH  - Oxides/chemistry
MH  - Prostate-Specific Antigen/metabolism
MH  - Prostatic Neoplasms/*diagnosis/metabolism
MH  - Reproducibility of Results
OTO - NOTNLM
OT  - Histidine-rGO
OT  - PSA
OT  - Saliva
OT  - Serum
OT  - Signal-off immunosensor
EDAT- 2019/05/12 06:00
MHDA- 2019/12/18 06:00
CRDT- 2019/05/12 06:00
PHST- 2019/03/02 00:00 [received]
PHST- 2019/04/27 00:00 [revised]
PHST- 2019/05/04 00:00 [accepted]
PHST- 2019/05/12 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2019/05/12 06:00 [entrez]
AID - S0731-7085(19)30549-7 [pii]
AID - 10.1016/j.jpba.2019.05.008 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2019 Aug 5;172:259-267. doi: 10.1016/j.jpba.2019.05.008. 
      Epub 2019 May 5.